米替福新（十六烷基磷酸胆碱）用于转移性实体瘤患者的剂量探索性研究。
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
作者信息
Verweij J, Planting A, van der Burg M, Stoter G
机构信息
Department of Medical Oncology, Rotterdam Cancer Institute/Daniel den Hoed Kliniek, The Netherlands.
出版信息
J Cancer Res Clin Oncol. 1992;118(8):606-8. doi: 10.1007/BF01211805.
Abstract
The ether lipid miltefosine (hexadecylphosphocholine) was orally given to patients with various tumours in a dose-finding study. All patients initially received a daily total dose of 100 mg, which in the absence of side-effects was increased to 150 mg and further to 200 mg. A total of 54 patients were entered and were evaluable for gastrointestinal toxicity. Nausea and vomiting were found to be dose-limiting; 22% of patients ultimately tolerated a dose of 100 mg, 59% tolerated a dose of 150 mg and 19% tolerated a dose of 200 mg. In addition 30% of patients developed renal dysfunction, which was thought to be related to the drug. No other toxicities were observed. For further phase II studies it is recommended that one starts with a dose of 150 mg daily, divided over three administrations.
摘要
在一项剂量探索研究中，给患有各种肿瘤的患者口服醚脂米托蒽醌（十六烷基磷酰胆碱）。所有患者最初每日总剂量为100mg，若无副作用则增至150mg，进而增至200mg。共有54例患者入组并可评估胃肠道毒性。发现恶心和呕吐为剂量限制性毒性；最终22%的患者耐受100mg剂量，59%的患者耐受150mg剂量，19%的患者耐受200mg剂量。此外，30%的患者出现肾功能障碍，认为与该药物有关。未观察到其他毒性。对于进一步的II期研究，建议起始剂量为每日150mg，分三次给药。
相似文献
1
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.米替福新（十六烷基磷酸胆碱）用于转移性实体瘤患者的剂量探索性研究。
J Cancer Res Clin Oncol. 1992;118(8):606-8. doi: 10.1007/BF01211805.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.
4
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物：网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
5
Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours.苯达莫司汀短时间输注的重复给药：一项针对晚期进展性实体瘤患者的I期研究。
J Cancer Res Clin Oncol. 2000 Jan;126(1):41-7. doi: 10.1007/pl00008463.
6
Concurrent low-dose cisplatin and thoracic radiotherapy in patients with inoperable stage III non-small cell lung cancer: a phase II trial with special reference to the hemoglobin level as prognostic parameter.不可切除的 III 期非小细胞肺癌患者同步低剂量顺铂与胸部放疗：一项特别参照血红蛋白水平作为预后参数的 II 期试验
J Cancer Res Clin Oncol. 2005 Apr;131(4):261-9. doi: 10.1007/s00432-004-0633-0. Epub 2004 Dec 23.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
8
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
9
Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.伊马替尼治疗不可切除和/或转移性胃肠道间质瘤患者：系统评价与经济学评估
Health Technol Assess. 2005 Jul;9(25):1-142. doi: 10.3310/hta9250.
10
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial.达帕唑胺联合贝达喹啉、地拉曼尼和莫西沙星治疗肺结核（PanACEA-DECODE-01）：一项前瞻性、随机、开放标签的2b期剂量探索试验。
Lancet Infect Dis. 2025 Jul 8. doi: 10.1016/S1473-3099(25)00289-0.
引用本文的文献
1
Safety profile of miltefosine in the treatment of cutaneous leishmaniasis.米替福新治疗皮肤利什曼病的安全性概况。
PLoS One. 2024 Dec 13;19(12):e0315710. doi: 10.1371/journal.pone.0315710. eCollection 2024.
2
Tolerability and Safety of Miltefosine for the Treatment of Cutaneous Leishmaniasis.米替福新治疗皮肤利什曼病的耐受性和安全性
Trop Med Infect Dis. 2024 Sep 19;9(9):218. doi: 10.3390/tropicalmed9090218.
3
Investigation of miltefosine-model membranes interactions at the molecular level for two different PS levels modeling cancer cells.研究米替福新与两种不同 PS 水平模拟癌细胞的模型膜在分子水平上的相互作用。
J Bioenerg Biomembr. 2024 Aug;56(4):461-473. doi: 10.1007/s10863-024-10025-y. Epub 2024 Jun 4.
4
Repositionable Compounds with Antifungal Activity against Multidrug Resistant Identified in the Medicines for Malaria Venture's Pathogen Box.在疟疾药物风险投资公司的病原体库中鉴定出的对多重耐药菌具有抗真菌活性的可重新定位化合物。
J Fungi (Basel). 2019 Oct 1;5(4):92. doi: 10.3390/jof5040092.
5
Exploring the new horizons of drug repurposing: A vital tool for turning hard work into smart work.探索药物再利用的新领域：将辛勤工作转化为聪明工作的重要工具。
Eur J Med Chem. 2019 Nov 15;182:111602. doi: 10.1016/j.ejmech.2019.111602. Epub 2019 Aug 8.
6
The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.米尔他福在南亚地区治疗晚期皮肤利什曼病的长期安全性和疗效：综述和荟萃分析。
PLoS Negl Trop Dis. 2019 Feb 11;13(2):e0007173. doi: 10.1371/journal.pntd.0007173. eCollection 2019 Feb.
7
Mast Cell Activation and Microtubule Organization Are Modulated by Miltefosine Through Protein Kinase C Inhibition.米替福新通过抑制蛋白激酶C调节肥大细胞活化和微管组织。
Front Immunol. 2018 Jul 9;9:1563. doi: 10.3389/fimmu.2018.01563. eCollection 2018.
8
A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani.从玛雅传统治疗师使用的一种植物中分离出的一种新型甾醇对治疗由杜氏利什曼原虫引起的内脏利什曼病有效。
ACS Infect Dis. 2015 Oct 9;1(10):497-506. doi: 10.1021/acsinfecdis.5b00081. Epub 2015 Sep 21.
9
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.一项针对难治性肿瘤患者口服磷脂酰肌醇-3激酶抑制剂（perifosine）并采用不同负荷给药方案的I期药代动力学研究。
Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3.
10
Effects of ionizing radiation in combination with Erufosine on T98G glioblastoma xenograft tumours: a study in NMRI nu/nu mice.电离辐射联合依氟鸟氨酸对 NMRI nu/nu 小鼠 T98G 胶质母细胞瘤移植瘤的影响：一项研究。
Radiat Oncol. 2012 Oct 18;7:172. doi: 10.1186/1748-717X-7-172.
本文引用的文献
1
Therapeutic activity of ET-18-OCH3 and hexadecylphosphocholine against mammary tumors in BD-VI rats.ET-18-OCH3和十六烷基磷酸胆碱对BD-VI大鼠乳腺肿瘤的治疗活性。
Lipids. 1987 Nov;22(11):927-9. doi: 10.1007/BF02535557.
2
Distribution and metabolism of hexadecylphosphocholine in mice.
Lipids. 1987 Nov;22(11):925-6. doi: 10.1007/BF02535556.
3
Metabolism of ether phospholipids and analogs in neoplastic cells.肿瘤细胞中醚磷脂及其类似物的代谢
Lipids. 1987 Nov;22(11):856-61. doi: 10.1007/BF02535544.
4
Characterization of the antitumor activity of hexadecylphosphocholine (D 18506).
Eur J Cancer Clin Oncol. 1988 Sep;24(9):1457-61. doi: 10.1016/0277-5379(88)90336-7.
5
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Acta Oncol. 1989;28(2):213-7. doi: 10.3109/02841868909111249.
Zotero 插件